Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity.

Antonio Ruggiero, Paola Coccia, Maria Scalzone, G. Attinà, Riccardo Riccardi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)


Irinotecan is a promising anticancer agent for the treatment of childhood cancer unresponsive to conventional chemotherapy. Its active metabolite, 7-ethyl-10 hydroxycamptothecin (SN-38) is glucuronidated by a uridine-diphosphoglucuronosyltransferase (UGT1A1) to form an inactive metabolite. It was supposed that patients with the UGT1A1*28 polymorphism would have a greater prevalence of elevated pretreatment serum bilirubin levels and higher toxicity. The aim of our study was to investigate the predictive value of pre-treatment bilirubin levels in the development of severe diarrhea in solid tumor patients treated with irinotecan. The survey included 14 pediatric patients with refractory sarcomas treated with irinotecan (CPT-11). Patients were grouped based on the development of mild (G0-2) or severe (G3) gastrointestinal toxicity. The simple linear regression model and the non-parametric paired wilcoxon test were adopted for the analysis. p <0.05 was judged to indicate a significant difference. The results showed a significant increase in severity of diarrhea with increasing total pre-treatment bilirubin. therefore, we propose that pre-treatment bilirubin levels can predict gastrointestinal toxicity in pediatric cancer.
Lingua originaleEnglish
pagine (da-a)693-697
Numero di pagine5
RivistaJournal of Chemotherapy
Stato di pubblicazionePubblicato - 2009


  • bilirubin level
  • childhood sarcoma
  • gastrointestinal toxicity
  • irinotecan


Entra nei temi di ricerca di 'Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity.'. Insieme formano una fingerprint unica.

Cita questo